AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06336564 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic floor muscle training
Description: Verbal information will be given about location, function and the correct way to contract the pelvic floor muscles (PFM). Participants will be instructed on how to perform The Knack, which is a pre-contraction of the PFM during some abdominal effort, such as coughing, sneezing or laughing. The exercises consist of two series of 10 maximum contractions sustained for 5 seconds and 10 seconds of relaxation and two series of 10 maximum rapid contractions with two seconds of maintenance and four seconds of relaxation, with one minute of rest between each series. Participants will be instructed to perform the same exercises at home (twice a day) and to fill out a training diary, allowing researchers to monitor and check whether the exercises are actually being performed. The protocol will be repeated with the researcher three times in total, every 30 to 40 days.
Study NCT06336564 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training
Description: Verbal information will be given about location, function and the correct way to contract the pelvic floor muscles (PFM). Participants will be instructed on how to perform The Knack, which is a pre-contraction of the PFM during some abdominal effort, such as coughing, sneezing or laughing. The exercises consist of two series of 10 maximum contractions sustained for 5 seconds and 10 seconds of relaxation and two series of 10 maximum rapid contractions with two seconds of maintenance and four seconds of relaxation, with one minute of rest between each series. Participants will be instructed to perform the same exercises at home (twice a day) and to fill out a training diary, allowing researchers to monitor and check whether the exercises are actually being performed. The protocol will be repeated with the researcher three times in total, every 30 to 40 days.
Study NCT06336564 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microablative Radiofrequency
Description: Patients will be placed in the lithotomy position and through speculum examination and under direct vision or guided by colposcope, sequential application of radiofrequency will be carried out on the vaginal walls and introitus. The Wavetronic 6000 Touch device will be used with the Megapulse HF FRAXX system (Loktal Medical Electronics, São Paulo, Brazil), equipped with an electronic energy fractionation circuit, connected to a vaginal pen with 64 microneedles, 200μm in diameter and 1 mm in length, mounted on a Teflon body and divided into a matrix of eight columns with eight needles each. In the vestibule and vaginal opening, 10% lidocaine spray will be applied three minutes before the procedure. Three applications will be carried out in the vagina/vaginal introitus, with an interval of 30 to 40 days.
Study NCT06494748 — intervention group
Intervention type: OTHER
Intervention: Follow up Decision
Description: 0: No need to follow up in Intensive Care Unit~1: Need to follow up in Intensive Care Unit
Study NCT04411836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafenoquine
Description: patients are treated with schizontocidal treatment plus a single dose of Tafenoquine (TQ).
Study NCT04411836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Primaquine
Description: patients are treated with schizontocidal treatment plus high dose PQ (total dose 7 mg/kg) unsupervised over 7 days (PQ7)
Study NCT05386056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg administered IV Q3W on Day 1 of each 3-week cycle, up to 35 administrations.
Study NCT05386056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sinoporphyrin Sodium
Description: 0.2mg/kg, intravenously on day -2 of cycle 1.
Study NCT05386056 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy
Description: PDT to primary site of ESCC will be given on day -1 of the treatment (24 hours after injection of DVDMS).
Study NCT05456165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GRT-C901
Description: An individualized neoantigen cancer vaccine using an adenovirus vector administered via intramuscular (IM) injections at Visit 1 and boost at Visit 6.
Study NCT05456165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GRT-R902
Description: An individualized neoantigen cancer vaccine using a self-amplifying mRNA (samRNA) vector administered via IM injection at Visits 2, 4, 9, and 12.
Study NCT05456165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Dose of 1680 mg administered once every 4 weeks (Q4W) via intravenous (IV) infusion at Visits 1-13.
Study NCT05456165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Dose of 30 mg administered via subcutaneous (SC) injection only with the first dose of GRT-C901 at Visit 1 and GRTR902 at Visit 2.
Study NCT05456165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Description: Administered according to standard of care.
Study NCT05456165 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adjuvant chemotherapy
Description: Administered according to standard of care.
Study NCT06198283 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Level LASER Therapy with Pressure Garment
Description: This group will be treated by low level laser therapy with pressure garment (8-10hrs a day) by Laplace' s Law method because it is more accurate since the range of pressures that can be delivered to a particular range of body circumferences varies depending on the fabric used and its particular tension- extension profile, the method is difficult to utilize manually and till present there is no available design tool to aid in its application. Pressure garments generate an increase in subdermal pressures in the range 9- 90 mmHg depending on the anatomical site. Garments over soft tissues generate pressures ranging from 9 to 33 mmHg. Over bony prominences the pressures range from 47 to 90 mmHg. 25mmHg pressure will be provided by garments and garments will be replaced in every 2 months
Study NCT06198283 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low Level LASER Therapy without Pressure Garment
Description: This group will receive low level LASER therapy (422-800nm) without pressure garment only for the duration of 6 weeks (3 days in a week with 20-30 minutes per session).
Study NCT05994287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: The patients received aspirin in a dose of 100 mg orally daily.
Study NCT05994287 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: The patients received aspirin in a dose of 100 mg orally daily.
Study NCT05994287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: The patients received ketorolac in a dose of 90 mg mg orally daily.
Study NCT05994287 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac
Description: The patients received ketorolac in a dose of 90 mg mg orally daily.
Study NCT05994287 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib
Description: The patients received celecoxib in a dose of 400 mg orally daily.
Study NCT05994287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: The patients received celecoxib in a dose of 400 mg orally daily.
Study NCT04908228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib and obinutuzumab
Description: Patients will receive fixed-duration treatment with ibrutinib and obinutuzumab.
Study NCT05532917 — intervention group
Intervention type: OTHER
Intervention: Gupta score
Description: The Gupta score is presented as an interactive risk calculation program in the 2014 guideline of the ACC/AHA. The Gupta score developed with this MICA model identified five predictors of perioperative myocardial infarction and cardiac arrest: type of surgery, functional status, creatinine increase (>130 mmol/L or >1.5 mg/dL), age, and American Association of Anesthesiologists (ASA) class. The frequency of cardiology consultation requests will be investigated according to the use of the Gupta score.
Study NCT05773443 — intervention group
Intervention type: DEVICE
Intervention: Digital biomarkers
Description: Digital application Smartwatch Sleep monitor Movement sensor EEG-sensor
Study NCT05975879 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: undenaturated collagen type II, methylsulfonylmethane, boswellia serrata, vitamin D3 (cholecalciferol), vitamin C (ARTNEO)
Description: Release form: capsules with an average weight of 585 mg. Active ingredients: MCM (methylsulfonylmethane) 300 mg, vitamin C (ascorbic acid) 80 mg, boswellia extract (65% boswellic acids) 50.05 mg, undenatured (native) type II collagen 40 mg, vitamin D3 (cholecalciferol) 400 IU.~Suggested Use: Adults, 1 capsule daily with meals.
Study NCT04511806 — intervention group
Intervention type: OTHER
Intervention: Registry
Description: This prospective registry and biorepository will collect clinical data and specimens for research in childhood cancer predisposition.
Study NCT06437002 — intervention group
Intervention type: BEHAVIORAL
Intervention: Mental Motor Chronometry (MMC) Task Hands and Feet and Whole Body
Description: The MMC will be used as a measure of MI and it is adapted for use in hands, feet, and the whole body as well as for online experimentation. The task is comprised of two conditions, MI, and motor execution, in which respectively participants will be asked to imagine and execute a movement sequence with both hands and feet and the whole body.~Hand movements: index and thumb opposition; thumb extension from the fist; middle finger crossed on the index finger; and extension of the index and the little fingers.~Foot movements: foot internal rotation, foot external rotation, foot dorsiflexion, and foot plantarflexion.~Whole-body movements: take a small bow, lift arms over the head and stand on the tips of the toes (stretch), extend hands forward and lower the backside (squats) and a small jump.~The types of movements required to be executed by participants are simple and do not require much energy. Therefore, people affected by AN and BN should be able to perform them without problems.
Study NCT06628635 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Exercise involving aerobics, isometrics, and stretching
Study NCT06628635 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Resting
Description: Resting
Study NCT06628414 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: transcranial Direct Current Stimulation
Description: transcranial Direct Current Stimulation
Study NCT06628414 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial Direct Current Stimulation
Description: transcranial Direct Current Stimulation
Study NCT04310059 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Folic acid
Description: women will be randomised into one of the three groups. Group A - Folic acid 5mg/day Group B - Folic acid 0.5mg/day Group C - Materna one tablet/day (a pregnancy supplement containing 0.6mg folic acid)
Study NCT04310059 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Materna
Description: Materna
Study NCT05602441 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VALID - diabetes supportive clubs
Description: The VALID - diabetes supportive clubs comprised diabetes classes and diabetes clubs, to highlight two prominent aspects of diabetes self-management: education and peer support.~The diabetes club meeting was held twice a month during a 9-month intervention, consisting of a focused delivery of the knowledge and discussion following the topic in the monthly class. Club meetings also included dedicated time for blood glucose testing and sharing experiences to deal with the difficulties of the periodic insurance examinations process. Finally, the club meetings provided the participants with emotional support to deal with the stigma and sadness in their daily lives.~Core messages aimed to strengthen daily self-management and boost the spiritual bond between individuals with T2D toward a healthy, happy life with T2DM. In addition, the intervention aimed to strengthen the capacities of grassroots health care workers in diabetes consultations and communication in rural communities.
Study NCT05975879 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Release form: capsules with an average weight of 585 mg. No active ingredients.
Study NCT06414980 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental
Description: The effect of suggestion given to patients with the olfactory memory method before the surgical operation on vital signs and systemic evaluation scoring during awakening.
Study NCT06388447 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Umbilical cord-mesenchymal stem cells
Description: One injection will be given at each papilla set with the volume of 0.1mL with 2.0 x 10⁶ cells per syringe at every visit. A total of 3 injections will be given at the interval of 6 weeks, with a total of 6.0 x 10⁶ cells for each interdental papilla at the end of the 3 injections. Every injection starts with locally application of local anesthetic. For the control group, participants will be injected with 0.9% sodium chloride after locally application of local anesthetic
Study NCT06388447 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Umbilical cord-mesenchymal stem cells
Description: One injection will be given at each papilla set with the volume of 0.1mL with 2.0 x 10⁶ cells per syringe at every visit. A total of 3 injections will be given at the interval of 6 weeks, with a total of 6.0 x 10⁶ cells for each interdental papilla at the end of the 3 injections. Every injection starts with locally application of local anesthetic. For the control group, participants will be injected with 0.9% sodium chloride after locally application of local anesthetic
Study NCT05400746 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pfs48/45 in Matrix-M
Description: Three doses of Pfs48/45 in Matrix-M at different doses
Study NCT05528536 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Description: A two-hour ACT will focus on enhancing participant's psychological flexibility towards pain. All sessions will be delivered face-to-face within their local community centre.
Study NCT05528536 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Art
Description: To be comparable with the experimental group, the Art session will be a two-hour long session which aims to share different art techniques, without any active components. All sessions will be delivered face-to-face within their local community centre.
Study NCT05528536 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: An hour of low-to-moderate resistance exercise aims to increase their strength and balance. All sessions will be delivered face-to-face within their local community centre.
Study NCT05528536 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Exercise
Description: An hour of low-to-moderate resistance exercise aims to increase their strength and balance. All sessions will be delivered face-to-face within their local community centre.
Study NCT05528536 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: treatment as usual within their community centres
Study NCT06141577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UI059
Description: take UI059 1cap/day for 7 days
Study NCT06141577 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: UIC202201
Description: take UIC202201 1cap/day for 7 days
Study NCT05268198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APR002
Description: Active Investigational Product
Study NCT05268198 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04729244 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CBD
Description: Hemp Oil
Study NCT04784013 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional CLOSE-guided pulmonary vein isolation
Description: Point-by-point RF delivery will be performed aiming for a contiguous circle enclosing the veins. RF will be delivered in a temperature and flow-controlled mode (QMODE, target temperature 45°C, low flow temperature 40°C, cut-off temperature 50°C) with a power of 35W(posterior)/50W(anterior) (irrigation flow at 4-15ml/min). RF will be delivered until an ablation index (AI) of ≥400 at the posterior wall/roof/south pole and ≥550 at the anterior wall.
Study NCT04784013 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: High power short duration pulmonary vein isolation
Description: Point-by-point RF delivery will be performed aiming for a contiguous circle enclosing the veins. RF will be delivered in temperature-controlled mode (QMode+, target temperature 55°C, cut-off temperature 65°C) with a power of 90W (irrigation flow at 2-8ml/min). RF will be delivered for 4 sec at both the posterior and anterior wall.
Study NCT05579886 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control Lens
Description: Daily disposable multifocal soft lens with 2 add design (2ADD) for 2 weeks
Study NCT05579886 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Lens
Description: Daily disposable multifocal soft lens with 3 add design (3ADD) for 2 weeks
Study NCT05009823 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Standard F75
Description: F-75 contains 75 kcal and 0.9 g protein per 100 ml.
Study NCT05009823 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Alternative F75 With CMV
Description: Cereal flour, oil, sugar, powdered milk with complex mineral-vitamin.
Study NCT05009823 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Alternative F75 Without CMV
Description: Cereal flour, oil, sugar, powdered milk without complex mineral-vitamin.
Study NCT05009823 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: F100
Description: 100 kcal and 3 g protein per 100 ml if the test of appetite at the end of the stabilization phase is negative (the child does not accept the Plumpynut)
Study NCT05009823 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Standard F75 + RUTF
Description: Standard F75 with ready to-use therapeutic food (Plumpynut) if the test of appetite at the end of the stabilization phase is positive
Study NCT05009823 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Alternative F75 with CMV + RUTF
Description: Alternative F75 + CMV with ready to-use therapeutic food (Plumpynut) if the test of appetite at the end of the stabilization phase is positive and the child received Alternative F75 + CMV during the stabilization phase
Study NCT05009823 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Alternative F75 without CMV + RUTF
Description: Alternative F75 - CMV with ready to-use therapeutic food (Plumpynut) if the test of appetite at the end of the stabilization phase is positive and the child received Alternative F75 - CMV during the stabilization phase
Study NCT05618457 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Aminoglycoside dose adjustment
Description: Eligible patients may have the aminoglycoside dose adjusted based on pathogen MIC, to attain the PK/PD target of Cam/MIC\~10 (8-12)
Study NCT04783181 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AAV BBP-631
Description: intravenous
Study NCT05402891 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium Carbonate
Description: Patients will be administered lithiumcarbonate by an oral tablet of 300mg once a day for a duration of 6 months. Starting dose is 200mg for the first 5 days, dosage will be then increased to 300mg. To limit adverse events and side-effects, the lowest effective dose will be administered. The target serum level of lithium is 0.20 - 0.40 mmol/L and this will be maintained by regular lithium level testing.
Study NCT06607731 — intervention group
Intervention type: OTHER
Intervention: Collecting data from medical records
Description: Data collected: clinical data (particularly pain), biological data, imaging.
Study NCT06309342 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PREVFUNKTION
Description: Functional profile and advice concerning cardiovascular fitness level, strength, mobility, balance and posture. Motivational interview and support in goalsetting to make lifestyle changes.
Study NCT06309342 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Physical activity measured with accelerometers. Functional examination. Medical examination and advice concerning weight measures, blood pressure and standard blood tests.
Study NCT06309342 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: Physical activity measured with accelerometers. Functional examination. Medical examination and advice concerning weight measures, blood pressure and standard blood tests.
Study NCT05737784 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRAX-222 - Initial Dose
Description: PRAX-222
Study NCT05737784 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRAX-222 - Initial Ascending Doses
Description: Ascending doses of PRAX-222
Study NCT05737784 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRAX-222 - Optional Ascending Doses
Description: Escalation of PRAX-222 dose(s)
Study NCT05737784 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRAX-222 - Fixed Doses
Description: Fixed-dose(s) of PRAX-222 not to exceed the maximum tolerated dose of PRAX-222
Study NCT05737784 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo procedure
Study NCT05737784 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo procedure
Study NCT06628726 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Liver biopsy
Description: surgical biopsy from liver